Processing

Please wait...

Settings

Settings

1. WO2007071738 - CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS

Publication Number WO/2007/071738
Publication Date 28.06.2007
International Application No. PCT/EP2006/070029
International Filing Date 20.12.2006
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
C07D 487/04 (2006.01)
A61K 31/519 (2006.01)
A61P 3/00 (2006.01)
A61P 7/00 (2006.01)
A61P 9/00 (2006.01)
A61P 25/00 (2006.01)
CPC
C07D 487/04
Applicants
  • NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basel, CH (AllExceptUS)
  • BAESCHLIN, Daniel Kaspar [CH/CH]; CH (UsOnly)
  • CLARK, David Edward [GB/GB]; GB (UsOnly)
  • DUNSDON, Stephen John [GB/GB]; GB (UsOnly)
  • FENTON, Garry [GB/GB]; GB (UsOnly)
  • FILLMORE, Amanda [GB/GB]; GB (UsOnly)
  • HARRIS, Neil Victor [GB/GB]; GB (UsOnly)
  • HIGGS, Christopher [GB/GB]; GB (UsOnly)
  • HURLEY, Christopher Antony [GB/GB]; GB (UsOnly)
  • KRINTEL, Sussie Lerche [DK/GB]; GB (UsOnly)
  • MACKENZIE, Robert Edward [GB/GB]; GB (UsOnly)
  • OSTERMANN, Nils [DE/DE]; DE (UsOnly)
  • SIROCKIN, Finton [FR/FR]; FR (UsOnly)
  • SUTTON, Jonathan Mark [GB/GB]; GB (UsOnly)
Inventors
  • BAESCHLIN, Daniel Kaspar; CH
  • CLARK, David Edward; GB
  • DUNSDON, Stephen John; GB
  • FENTON, Garry; GB
  • FILLMORE, Amanda; GB
  • HARRIS, Neil Victor; GB
  • HIGGS, Christopher; GB
  • HURLEY, Christopher Antony; GB
  • KRINTEL, Sussie Lerche; GB
  • MACKENZIE, Robert Edward; GB
  • OSTERMANN, Nils; DE
  • SIROCKIN, Finton; FR
  • SUTTON, Jonathan Mark; GB
Agents
  • LIGIBEL, Jean-Marc; Novartis AG Lichtstrasse 35 CH-4056 Basel, CH
Priority Data
60/753,38223.12.2005US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS
(FR) COMPOSES HETEROCYCLIQUES CONDENSES UTILES EN TANT QU’INHIBITEURS DE DPP-IV
Abstract
(EN)
The invention provides novel deazaxanthine and deazahypoxanthine compounds, of formula (I), wherein X is -CH= and Y is =N-; or X is -C(O)- and Y is -N(R3)-; The compounds may be useful in the therapy of diseases and conditions in wich dipeptidylpeptidase-IV (DPP-IV) is implicated.
(FR)
L’invention concerne de nouveaux composés de déazaxanthine et de déazahypoxanthine, de formule (I), dans laquelle X représente -CH= et Y représente =N- ; ou X représente -C(O)- et Y représente -N(R3)-. Ces composés peuvent être utiles pour le traitement de maladies et d’états impliquant la dipeptidylpeptidase-IV (DPP-IV).
Other related publications
Latest bibliographic data on file with the International Bureau